summari due report result believ
consensu sale forecast sale reason
consensu ep seem high take account time
asp divestitur ep estim consensu
reflect close asp divestitur close
recognit gain asset sale compar mix
consensu expect close analysi im data
suggest strength jnj us pharmaceut busi see
pharma tracker start page increas
forecast modestli coupl product see uncertainti
relat potenti chang discounting/reb accrual
result generic/biosimilar competit would depress
report sale expect maintain guidanc
organ sale growth ex-fx acquisitions/divestitur
report ep analysi indic fx headwind
closer vs jnj guidanc expect
compani larg absorb increment impact
sale includ fx headwind
organ sale growth jnj full year guidanc
organ sale growth face easiest yr/yr comp
analysi im sales/rx trend indic
stronger-than-expect perform across multipl product
partli off-set uncertainti around discounting/rebating/pric
adjust lower invokana sale consum nielsen data
show acceler us consum growth low-singl digit
mid-singl digit growth ytd
underli guidanc like intact fx headwind
probabl wors guid organ sale growth
report ep midpoint base
outlook expect underli guidanc remain
intact especi earli year howev estim fx
headwind wors jnj guidanc
year suggest report sale declin could closer
vs current guidanc continu anticip
jnj medic devic consum sale growth acceler
pharma sale growth also improv later
year addit new launch anniversari us
gener zytiga competit includ slightli wors fx impact
forecast sale estim organ
report consensu low-end
report sale guidanc rang although
pend auri acquisit exclud guidanc expect
absorb increment sale expens
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
consensu ep like mis-model due time divestitur ep estim reflect
close asp divestitur consist guidanc actual deal close
believ consensu forecast high like reflect mis-model estim
gain asset asp sale street forecast probabl reflect mix assumpt close
asp sale thu inflat ep potenti depress ep estim ep
us pharma product trend expect consum may in-lin
due report result estim total sale organ ep
vs consensu respect im analysi show key us
pharma product perform in-lin expect although rais
estim zytiga stelara extrapol im sale suggest potenti modest upsid product like
remicad imbruvica estim organ pharma sale growth vs
deceler reflect impact us gener zytiga biosimilar procrit competit
consum estim organ growth analysi nielsen data point
growth us consum slightli estim us consum growth forecast
take account slightli easier comp addit continu roll
new babi care brand could boost ou consum perform medic devic model
organ sale growth easi comp growth year ago
forecast assum fx headwind slightli wors month ago
summari im analysi key us pharmaceut product im data suggest stronger-than-
expect perform number drug us base im analysi rais
us sale forecast stelara zytiga lower
estim invokana extrapol im sale also suggest potenti
upsid sale remicad imbruvica xarelto simponi pah franchis chang
forecast howev due uncertainti potenti impact rebating/discount competit
product like remicad xarelto possibl price adjustment/accru relat generic/biosimilar
competit zytiga procrit forecast us pharmaceut sale yr/yr growth
vs organ growth monthli product tracker detail start page
us net drug price fell list drug price increas earli expect
accord jnj us transpar report issu net us drug price fell
compar low mid-singl digit increas list price discount
rebat fee us drug rose last year compar increas
rais price across much us drug portfolio similar magnitud price
increas similar lower compani histor price action price increas rang
darzalex procrit xarelto invega sustenna hand older
alreadi generic product like levaquin ditropan xl expect much price increas
net discounts/rebates/fe
consum growth expect acceler jnj ww consum sale grew organ
includ us growth forecast slight acceler organ sale growth
ww us base continu roll new babi care brand rel
easi comp comparison analysi aggreg nielsen data
compani report secur llc estim organ growth adjust fx acquisitions/divestitur sell day prior price adjust pharma venezuela anima exit pharma overal growth adjust remicad rebat ex-adjust organ growth pharma overal cardiovascular cerenovu neurovascular intervent solut start diabet adjust anima exit impact amo acqusit includ ex-fx growth rate atln acquisit includ ex-fx growth rate key busi segmentsex-fx growthorgan growth johnson johnson
suggest sale growth acceler
forecast figur nielsen data appear trend direct in-lin report us consum
sale organ growth time figur ww basi forecast consum sale
organ growth includ us sale
nielsen sale base aggreg data
nielsen sale base aggreg data
see sale growth guidanc remain intact guid organ sale growth ex-fx
acquisit divestitur includ headwind gener biosimilar
competit base expect expect guidanc remain larg unchang
caveat limit visibl busi outsid us pharma/consum year ago
outperform despit softer us pharma sale rais top-lin growth guidanc
call given growth headwind believ like guid conserv
suggest room improv especi year progress new product
launch recent fx analysi suggest currenc headwind remain year
suggest headwind also unchang expect jnj consum medic devic
busi grow slightli in-lin market pharma sale grow market
net organ sale growth report sale yr/yr declin figur
ep guidanc like remain unchang guid report ep guidanc
growth midpoint rang guidanc includ fx headwind may
slightli wors expect absorb increment drag oper ep guidanc
growth pend acquisit auri guidanc yet
would expect materi impact bottom-lin outlook model assum
complet share buy-back program could contribut annual
earn accret complet buy-back program
estmkt compani report secur llc estim organ growth report ex-fx adjust sell day differ venezuela impact prior period price johnson johnson
us remicad sale seem in-lin base im trend forecast us remicad ex-export
sale yr/yr declin slightli trend easier comp
us remicad sale fell due headwind rebat adjust exclud
rebat adjust estim us remicad sale fall yr/yr consist
declin full year estim appear reason base im analysi use recent
histor ratio report sale im sale although note histor ratio
volatil contract biosimilar eros specif im sale declin low-singl digit
report sale fell extrapol im sale show remicad sale fell yr/yr
compar estim sale declin
biosimilar remicad penetr appear stall im sale show biosimilar remicad ramp
that mostli flattish sinc sale june compar
februari figur sale second biosimilar launch month ago
doubl recent sale pfe/celltrion first-to-market
biosimilar littl chang recent meanwhil trail
averag remicad im sale remain rang although report sale declin
increas rebat discount pfe/celltrion inflectra account nearli
modest impact biosimilar procrit far pfe biosimilar procrit retacrit launch im
sale show retacrit sale februari decemb compar jnj procrit
sale respect retacrit uptak far appear ahead inflectra initi uptak
although still earli launch
us darzalex sale forecast seem reason model us darzalex sale
yr/yr increas ww sale growth us forecast slightli
extrapol im sale thu appear reason continu forecast
ww sale slightli genmab estim next key catalyst darzalex
approv maia data front-lin use us file subq formul
expect year accord brandimpact darzalex held share mm market
februari novemb drug first approv figur
line darzalex maintain lead share februari figur darzalex held overal
market share survey reflect share front-lin use
potenti slight upsid us imbruvica estim forecast us imbruvica revenu
impli end-us sale forecast seem slightli conserv vs
extrapol im sale closer impli revenu guid
us growth translat end-us sale revenu vs
estim rx perspect roll imbruvica trx volum grew
weekli averag figur reflect double-count rx volum year
ago report im recent imbruvica growht trend closer growth unclear
chang im report method affect trend phase imbruvica mono-
combo therapi data differ patient popul watch wait patient expect
emerg reinforc drug benefit front-lin use
lower us invokana sale forecast rx declin share loss acceler lower
us invokana sale estim yr/yr declin base softer-than-
expect extrapol im sale trend soft im sale coupl acceler declin rx
volum market share jan-feb indic us neg chang invokana
contract formulari statu start invokana franchis monthli volum fell
yr/yr jan/feb acceler compar declin figur weekli im data
first three week march also show acceler yr/yr nrx volum declin figur
invokana franchis nrx share class also fell decemb januari
encourag invokana rx volum declin began slow somewhat
perhap relat posiiv efficaci find credenc renal outcom trial recent im
trend suggest invokana sale continu declin perhap even faster pace still
possibl clean safeti profil credenc may encourag fda consid remov
black box warn invokana labl may help turnaround invokana sale time
invokana lose share jardianc earli februari invokana/invokamet nrx market
share fell sharpli decemb juli figur lost share
pick bi/lli jardianc franchis whose nrx share jump decemb
februari jardianc mark share increas point past year like driven continu
benefit posit empa-reg outcom trial show drug lower cardiovascular risk
without increas amputation/fractur risk azn farxiga/xiguo xr share slip modestli
februari decemb categori nrx growth averag earli compar
growht
increas us zytiga sale estim us gener zytiga competit began decemb
first full quarter impact includ jnj author gener increas
us zytiga sale estim yr/yr declin still well
extrapol im sale trend im sale suggest us zytiga sale could closer
expect discounting/reb acrrual lower figur dont know much also
launch gener zytiga hold share compar zytiga share
apotex gener share myl gener share higher brand zytiga sale
contribut gener believ forecast reason possibl conserv
erleada uptak continu earli year sinc launch erleada us sale annual
base februari im sale annual im sale six month ago
howev monthli erleada trx nrx volum somewhat flattish first two month
compar first two month estim us erleada sale seem
reason base extrapol im sale data
chang xarelto forecast despit stronger im sale trend forecast xarelto sale
yr/yr growth compar extrapol im sale suggest sale closer
howev chang forecast seen rebating/discount play import role
competit market made histor reported/im sale ratio less reliabl forecast
addit report two consecut quarter xarelto sale declin part due prior
period price adjust make us bit cautiou price adjust monthli
nrx volum show yr/yr growth jan/feb consist trend figur
overal novel oral anticoagul noac market growth februari eliqui maintain
lead among noac share m/m follow xarelto share
m/m past year xarelto lost share eliqui gain share figur
noac account oral anticoagul nrx vs end
xarelto launch figur fda approv xarelto compass data mid-octob
expand use includ cad/pad coronari arteri disease/peripher arteri diseas recent im sale
rx trend yet indic xarelto share recaptur growth reacceler
us invega sustenna/trinza sale consist im trend forecast us sale
growth yr/yr within extrapol im sale rang im sale
growth sustenna trinza jan/feb trend im sale jnj long-
act inject atyp laia franchis sustenna trinza risperd consta jan/feb
low-singl digit growth consist teen growth seen first three quarter
figur us laia market maintain sizeabl lead franchis nrx market
share past month ostuka abilifi maintena hold share
yr/yr aristada share yr/yr figur
rais us stelara sale forecast base stronger im trend increas us
stelara sale yr/yr growth base extrapol im sale suggest
report sale could approach howev rais forecast due uncertainti
around rebating/discount chang especi start new year stelara im sale grew
jan/feb growth suggest continu momentum despit strong uptak
tremfya figur trx volum specialti suggest crohn remain key growth driver
monthli written gastroenterolog specialist stelara rose well
past year rheumatologist dermatologist stelara
approv ulcer coliti could help maintain stelara growth momentum
us tremfya sale in-lin forecast us tremfya sale
estim appear consist extrapol im sale nearli month
market tremfya im sale annual base jan/feb data comparison
nv cosentyx lli taltz sale annual time post-launch current
cosentyx im sale annual taltz im sale annual weekli tremfya
volum appear track slightli ahead stelara remain behind cosentyx taltz
time post-launch figur continu view tremfya import growth driver jnj
pharma franchis despit cannib stelara sale among dermatologist newest competitor
ilumya sun pharma appear gain much traction month market
chang us simponi/aria sale forecast estim us simponi/aria sale
yr/yr growth slightli extrapol im sale rang
jan/feb simponi im sale grew yr/yr aria im sale grew togeth drive franchis
growth slightli acceler im sale growth figur
us pah sale could modestli outperform expect opsumit tracleer uptravi figur
togeth account us pah peripher arteri hypertens sale extrapol
im suggest potenti modest upsid estim although ratio report im
sale choppi estim us opsumit sale compar extrapol im
sale closer uptravi forecast us sale compar extrapol im
data closer tracleer forecast us sale compar extrapol im
sale closer
analysi independ arriv secur llc basi data
inform im respons relianc recipi either data analys
reportedim us split im health incorpor nation sale perspect compani report secur llc estim sale estim base commentari im data forecast us imbruvica sale assum record end-us sale report consist third month perform prior quarter assum march im sale repres medic technolog
compris mostli pfe/celltrion inflectra
figur darzalex hold posit line multipl myeloma market
figur darzalex maintain lead line multipl myeloma market
follow chang imbruvica ndc nation drug code im report doubl count rx
one distributor late march continu part year
rxtrxnrxfeb cll approvedmar front-lin cll approvedjul r/r cll label expans includ mutat jan waldenstrm macroglobulinemia approvedaug graft-vs-host-diseas cgvhd growthmonthli trxtrx volumetrx rx y/i present canva data ada meet -posit efficaci safeti trade-off strengthen warn risk acut kidney add black box warn leg foot amput risk medic technolog
figur invokana franchis continu lose share
figur zytiga erleada monthli volum growth
new oral anticoagul includ pradaxa xarelto eliqui savaysa
growth trxtrx growthtrx nrxnrxoral anticoagulantsnew oral anticoagul new oral anticoagul xarelto spaf approvedeliqui spaf approvedeliqui dvt prevent approvedsavaysa spaf approvedeliqui dvt treatment approvedxarelto dvt treatment approv medic technolog
figur stelara im sale fall growth slow recent
growthim sale sustenna trinza consta sale yoy im sale growthsustenna launch aug launch jun market sharealk aristadaotsuka abilifi maintenajnj sinvega sustenna trinza risperd growthsal stelara tremfya salesstelara tremfya yoy growthtremfya launch jul launch may crohn launch sep launch jan johnson johnson
figur atln opsumit im sale growth continu
figur atln tracleer im sale continu declin
figur atln uptravi im sale remain solid launch trajectori
price target nc
price target impli cash ep base sum-of-the-part
analysi risk includ delay pipelin product unexpect delay deal integr unexpect
deterior industri
expect growth slow due multipl headwind see growth re-acceler
johnson johnson world comprehens broadli base healthcar compani
consum pharmaceut medic devic market medic devic segment consist primarili
product cardiovascular orthoped surgic vision compani report sale
year-over-year organ basi
